SCHEMBL5729693

SCHEMBL5729693

O=C(c1cccc(OCCC2CCCN2)c1)c1c(-c2ccc(O)cc2)noc1-c1ccc(O)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.42
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHEK2 O96017 1/20 0.40
SLC6A2 P23975 1/20 0.37
HRH2 P25021 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2B P41595 1/20 0.37
SLC6A3 Q01959 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
SSTR2 P30874 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5729303 0.97 CHEK2 (0.42) CHEK1CHRNB4CHRNA3CHEK2SLC6A2
SCHEMBL5729577 0.93 CHEK1 (0.42) CHEK1CHRNB4CHRNA3CHEK2SSTR2
Hydrochloric Acid SCHEMBL6311273 0.92 CHEK1 (0.42) CHEK1CHRNB4CHRNA3CHEK2SSTR2
SCHEMBL5731064 0.89 CHEK2 (0.45) CHEK1CHEK2SLC6A2HRH2HTR2A
SCHEMBL5729282 0.87 CHEK2 (0.49) CHEK1CHEK2SLC6A2HRH2HTR2A
SCHEMBL6304487 0.85 CHEK2 (0.46) CHEK1CHRNB4CHRNA3CHEK2SLC6A2
SCHEMBL5729625 0.83 CHEK2 (0.46) CHEK1CHEK2SSTR2
SCHEMBL5729507 0.83 CHEK2 (0.46) CHEK1CHEK2SSTR2
SCHEMBL5729019 0.81 CHEK2 (0.40) CHEK1CHEK2SLC6A2SSTR2LMNA
SCHEMBL5729686 0.81 ESR1 (0.52) SLC6A2HRH2HTR2AHTR2BSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1102755-B1 SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORP (US) 2006-01-04 EP disclosed
US-6869969-B2 Estrogen receptor modulators CHIRON CORPORATION (US) 2005-03-22 US disclosed
US-6743815-B2 OSTEOPOROSIS; ENDOMETRIOSIS; ALZHEIMER'S DISEASE CHIRON CORPORATION 2004-06-01 US disclosed
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors CHIRON CORPORATION 2004-05-27 US disclosed
US-20030065012-A1 Estrogen receptor modulators CHIRON CORPORATION (US) 2003-04-03 US disclosed
US-6387920-B2 ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE CHIRON CORPORATION 2002-05-14 US disclosed
US-20010036956-A1 Estrogen receptor modulators HUEBNER VERENA D (US) 2001-11-01 US disclosed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036956-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CHEK1 2950/4885CHRNB4 429/4885CHRNA3 153/4885
US-20030065012-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 CHEK1 2950/4885CHRNB4 429/4885CHRNA3 153/4885
US-20040102498-A1 Cycloalkylene compounds with substituents as anticancer agents, atheriosclerosis and estrogen receptors ESR2, GPER1, ESR1 CHEK1 1227/4885CHRNB4 1197/4885CHRNA3 449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.